Results 31 to 40 of about 24,853 (244)

Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

Pediatric Rheumatology Online Journal, 2021
Background This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Methods Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between ...
Ying Chi, Rong Liu, Zhi-xuan Zhou, Xiao-dong Shi, Yu-chuan Ding, Jian-guo Li   +5 more
doaj   +1 more source

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

Journal of Clinical Oncology, 2023
PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need.
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, F. Palandri, T. Devos, F. Passamonti, R. Rampal, A. Mead, Gabriella Hobbs, J. Scandura, M. Talpaz, N. Granacher, T. Somervaille, R. Hoffman, M. Wondergem, M. Salama, G. Colak, J. Cui, J. Kiladjian, A. Vannucchi, S. Verstovsek, N. Curto-Garcia, C. Harrison, V MNSSVKR GUPTA   +23 more
semanticscholar   +1 more source

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD

Case Reports in Oncological Medicine, 2020
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to ...
Philip T. Sobash, Achuta K. Guddati, Vamsi Kota   +2 more
doaj   +1 more source

Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study

Frontiers in Pharmacology, 2021
Background: Chronic active Epstein-Barr virus (CAEBV) infection is one of the EBV-positive T- or NK-cell lymphoproliferative diseases. There is no safe and effective treatment currently and the only proven curable therapy is allogeneic hematopoietic stem
Yue Song, Jingshi Wang, Yini Wang, Zhao Wang   +3 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review

Clinical Pharmacokinetics, 2023
Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways.
T. Y. J. Appeldoorn, T. O. Munnink, L. Morsink, M. L. Hooge, D. Touw   +4 more
semanticscholar   +1 more source

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Nature Medicine
Janus kinase (JAK) inhibitors provide limited depth and durability of response in myelofibrosis. We evaluated pelabresib—a bromodomain and extraterminal domain (BET) inhibitor—plus ruxolitinib (a JAK inhibitor) compared with placebo plus ruxolitinib as ...
R. Rampal, S. Grosicki, Dominik Chraniuk, E. Abruzzese, P. Bose, A. Gerds, A. Vannucchi, F. Palandri, Sung‐Eun Lee, Vikas Gupta, A. Lucchesi, Stephen T. Oh, Andrew T Kuykendall, Andrea Patriarca, A. Álvarez-Larrán, Ruben A. Mesa, J. Kiladjian, Moshe Talpaz, Joseph M Scandura, D. Lavie, Morgan Harris, Sarah-Katharina Kays, Qing Li, Rainer Boxhammer, Barbara Brown, A. Jegg, C. Harrison, John O. Mascarenhas   +27 more
semanticscholar   +1 more source

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial

Cancer Medicine, 2021
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinical ...
David E. Spaner, Yuxuan Luo, Guizhei Wang, Jennifer Gallagher, Hubert Tsui, Yonghong Shi   +5 more
doaj   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design

Future Oncology
Selinexor is an investigational, selective oral XPO1 inhibitor that may inhibit myelofibrosis (MF)-relevant JAK/STAT and non-JAK/STAT pathways with potential synergy with ruxolitinib.
J. Mascarenhas, Keri Maher, R. Rampal, P. Bose, Nikolai Podoltsev, J. Hong, Yi Chai, Steve Kye, M. Method, C. Harrison   +9 more
semanticscholar   +1 more source

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)

Cancer
Myelofibrosis (MF) significantly impacts patients’ overall survival (OS) and quality of life (QOL). This prospective study analyzed ruxolitinib dosing patterns and associated clinical outcomes in patients with MF over 12 months.
M. Breccia, F. Palandri, M. Martelli, F. Mendicino, A. Malato, G. Palumbo, S. Sibilla, N. Di Renzo, E. Abruzzese, Sergio Siragusa, M. Crugnola, C. Selleri, Fabrizio Pane, P. Sportoletti, B. Martino, S. Impera, A. Ricco, Maria-Luisa Langella, P. Ditonno, G. Carli, F. Itri, A. Liberati, T. Urbano, A. Tafuri, V. Polizzi, Domenico Pastore, E. Morsia, G. Benevolo, G. Micucci, G. Farina, M. Bonifacio, E. Elli, A. Gardellini, Valerio De Stefano, G. Caocci, A. Falcone, D. Vallisa, M. Brociner, M. Tiribelli, G. Binotto, Barbara Pocali, F. Cavazzini, S. Tomassetti, F. Lunghi, Mauro Di Ianni, Alessandro Allegra, Barbara Anaclerio, S. Mazzotta, N. Orofino, F. Gherlinzoni, Chiara Castiglioni, M. Landoni, D. Valsecchi, Michela Magnoli, Paola Guglielmelli, F. Passamonti   +55 more
semanticscholar   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source